FDA Approves Adaptimmune's Groundbreaking T-Cell Therapy for Rare Cancer

Tecelra offers new hope for synovial sarcoma patients with limited treatment options

Tecelra is the first gene therapy approved in the U.S. that uses a patient's own T-cells to target cancer.
The therapy, priced at $727,000, received accelerated approval and requires further confirmatory trials.
Synovial sarcoma affects about 1,000 people annually in the U.S., primarily young adults.
In clinical trials, Tecelra showed a 43.2% response rate among participants, with effects lasting an average of six months.
The treatment carries a risk of severe cytokine release syndrome, a dangerous immune response.